miR-548d-3p inhibits osteosarcoma by downregulating KRAS
Jianhua Chen(Hunan Cancer Hospital), Quan Yuan(China Medical University), Chongnan Yan(China Medical University), Shihan Zhen(China Medical University), Honghao Yu(Tongji Hospital)
Cited by 28
Related Papers
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
Exosomes: The emerging mechanisms and potential clinical applications in dermatology
|International Journal of Biological Sciences|2024|72
Current landscape of personalized clinical treatments for triple-negative breast cancer
|Frontiers in Pharmacology|2022|44
Landscape of the epigenetic regulation in wound healing
|Frontiers in Physiology|2022|39
Synthetic biodegradable polymer materials in the repair of tumor-associated bone defects
|Frontiers in Bioengineering and Biotechnology|2023|34